HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SU 11652

a tyrosine kinase inhibitor; amino acid sequence in first source

Also Known As:

SU-11652; SU11652

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - SU 11652: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - SU 11652: 1

Experts

1.	Ellegaard, Anne-Marie: 1 article (10/2013)
2.	Groth-Pedersen, Line: 1 article (10/2013)
3.	Jäättelä, Marja: 1 article (10/2013)
4.	Kirkegaard, Thomas: 1 article (10/2013)
5.	Klumperman, Judith: 1 article (10/2013)
6.	Nylandsted, Jesper: 1 article (10/2013)
7.	Oorschot, Viola: 1 article (10/2013)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 10/01/2013 - "Remarkably, SU11652 killed multidrug-resistant Du145 prostate cancer cells as effectively as the drug-sensitive parental cells, and subtoxic concentrations of SU11652 effectively inhibited multidrug-resistant phenotype in Du145 prostate cancer cells. "
2.	Neoplasms (Cancer) 10/01/2013 - "The significantly stronger lysosome-targeting activity of SU11652 suggests that it may display better efficacy in cancer treatment than sunitinib, encouraging further evaluation of its anticancer activity in vivo. " 10/01/2013 - "Furthermore, our data provide a rationale for novel approaches to target drug-resistant cancers by combining classic chemotherapy with sunitinib or SU11652."

Related Drugs and Biologics

1.	Sunitinib (Sutent)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)